Literature DB >> 25130860

Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.

Margaret S Sozio1, Naga Chalasani.   

Abstract

Entities:  

Year:  2014        PMID： 25130860      PMCID： PMC4211995          DOI： 10.1002/hep.27363

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  17 in total

1.  Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2005-07       Impact factor: 25.083

Review 2.  The coagulopathy of chronic liver disease.

Authors:  Armando Tripodi; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

Review 3.  Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.

Authors:  Veronica Yank; C Vaughan Tuohy; Aaron C Logan; Dena M Bravata; Kristan Staudenmayer; Robin Eisenhut; Vandana Sundaram; Donal McMahon; Ingram Olkin; Kathryn M McDonald; Douglas K Owens; Randall S Stafford
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

4.  Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study.

Authors:  D E Bernstein; L Jeffers; E Erhardtsen; K R Reddy; S Glazer; P Squiban; R Bech; U Hedner; E R Schiff
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

5.  Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.

Authors:  Gretchen M Brophy; Christina L Candeloro; Jaime R Robles; Donald F Brophy
Journal:  Ann Pharmacother       Date:  2013-03-27       Impact factor: 3.154

6.  The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors.

Authors:  Lucio Amitrano; Maria Anna Guardascione; Francesco Manguso; Raffaele Bennato; Antonio Bove; Claudio DeNucci; Giovanni Lombardi; Rossana Martino; Antonella Menchise; Luigi Orsini; Salvatore Picascia; Elisabetta Riccio
Journal:  Am J Gastroenterol       Date:  2012-09-25       Impact factor: 10.864

7.  Improved survival after variceal bleeding in patients with cirrhosis over the past two decades.

Authors:  Nicolas Carbonell; Arnaud Pauwels; Lawrence Serfaty; Olivier Fourdan; Victor George Lévy; Raoul Poupon
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

8.  Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices.

Authors:  Rafael Romero-Castro; Manuel Jimenez-Saenz; Francisco Pellicer-Bautista; Manuel Gomez-Parra; Federico Argüelles Arias; Maria D Guerrero-Aznar; Angel Sendon-Perez; Juan M Herrerias-Gutierrez
Journal:  Clin Gastroenterol Hepatol       Date:  2004-01       Impact factor: 11.382

9.  Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

Authors:  Jaime Bosch; Dominique Thabut; Agustín Albillos; Nicolas Carbonell; Julius Spicak; Julien Massard; Gennaro D'Amico; Didier Lebrec; Roberto de Franchis; Søren Fabricius; Yan Cai; Flemming Bendtsen
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

10.  Improved patient survival after acute variceal bleeding: a multicenter, cohort study.

Authors:  Naga Chalasani; Charles Kahi; Fritz Francois; Amar Pinto; Atul Marathe; Edmund J Bini; Prashant Pandya; Shanti Sitaraman; Jianzhao Shen
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864
View more
  1 in total

1.  Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope.

Authors:  Xingshun Qi; Chun Ye; Xiaozhong Guo
Journal:  Arch Med Sci       Date:  2017-01-23       Impact factor: 3.318
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.